| Nome |
# |
|
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial, file e309ade2-d568-3969-e053-3a05fe0a2c94
|
1.318
|
|
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study, file e309ade3-b15a-3969-e053-3a05fe0a2c94
|
1.094
|
|
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial, file e309ade2-d573-3969-e053-3a05fe0a2c94
|
944
|
|
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial, file e309ade4-becd-3969-e053-3a05fe0a2c94
|
784
|
|
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials, file e309ade4-7f67-3969-e053-3a05fe0a2c94
|
347
|
|
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management, file e309ade3-e7e4-3969-e053-3a05fe0a2c94
|
335
|
|
Controlled trial of budesonide-formoterol as needed for mild asthma, file e309ade2-cf33-3969-e053-3a05fe0a2c94
|
310
|
|
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial, file e309ade4-82cd-3969-e053-3a05fe0a2c94
|
285
|
|
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial, file e309ade2-d388-3969-e053-3a05fe0a2c94
|
243
|
|
Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6, file 02d33c64-6dec-4ebf-a439-a19c7c98aa43
|
213
|
|
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, file e309ade4-c029-3969-e053-3a05fe0a2c94
|
181
|
|
Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma, file e309ade4-7604-3969-e053-3a05fe0a2c94
|
179
|
|
Inhaled corticosteroids in COPD: Friend or foe?, file e309ade3-49d4-3969-e053-3a05fe0a2c94
|
156
|
|
Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies, file e309ade4-a288-3969-e053-3a05fe0a2c94
|
149
|
|
Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells, file e309ade2-d027-3969-e053-3a05fe0a2c94
|
135
|
|
Extrafine triple therapy in patients with asthma and persistent airflow limitation, file e309ade4-6f73-3969-e053-3a05fe0a2c94
|
130
|
|
ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma, file e309ade4-8db0-3969-e053-3a05fe0a2c94
|
123
|
|
Efficacy and Safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma, file e309ade4-6c79-3969-e053-3a05fe0a2c94
|
103
|
|
Use of mucolytics in COPD: A Delphi consensus study, file e309ade4-cb1f-3969-e053-3a05fe0a2c94
|
95
|
|
Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program, file e309ade4-6bfc-3969-e053-3a05fe0a2c94
|
87
|
|
Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review, file e309ade2-c7fc-3969-e053-3a05fe0a2c94
|
86
|
|
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD, file e309ade2-d1c5-3969-e053-3a05fe0a2c94
|
86
|
|
Clinical and Pathologic Factors Predicting Future Asthma in Wheezing Children. A Longitudinal Study, file e309ade4-cd17-3969-e053-3a05fe0a2c94
|
83
|
|
Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium, file e309ade4-b8c5-3969-e053-3a05fe0a2c94
|
77
|
|
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma, file e309ade4-8b10-3969-e053-3a05fe0a2c94
|
72
|
|
Benralizumab for the prevention of COPD exacerbations, file e309ade4-cd8f-3969-e053-3a05fe0a2c94
|
72
|
|
Caring for patients with COPD and COVID-19: a viewpoint to spark discussion, file e309ade4-862b-3969-e053-3a05fe0a2c94
|
69
|
|
Burden of Pertussis in COPD: A Retrospective Database Study in England, file e309ade4-4eff-3969-e053-3a05fe0a2c94
|
68
|
|
Current controversies in chronic obstructive pulmonary disease: A report from the global initiative for chronic obstructive lung disease scientific committee, file e309ade4-73c2-3969-e053-3a05fe0a2c94
|
66
|
|
Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis, file e309ade4-7f80-3969-e053-3a05fe0a2c94
|
64
|
|
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease, file e309ade2-d56b-3969-e053-3a05fe0a2c94
|
63
|
|
IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis, file e309ade4-9727-3969-e053-3a05fe0a2c94
|
57
|
|
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline, file e309ade3-b15e-3969-e053-3a05fe0a2c94
|
55
|
|
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal, file e309ade4-aef3-3969-e053-3a05fe0a2c94
|
54
|
|
Moving towards a Treatable Traits model of care for the management of obstructive airways diseases, file e309ade4-f59c-3969-e053-3a05fe0a2c94
|
53
|
|
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation, file e309ade3-4251-3969-e053-3a05fe0a2c94
|
52
|
|
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019, file e309ade3-f58a-3969-e053-3a05fe0a2c94
|
52
|
|
Prevention of COPD exacerbations: A European Respiratory Society/ American Thoracic Society guideline, file e309ade4-9724-3969-e053-3a05fe0a2c94
|
52
|
|
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer, file e309ade2-a3c7-3969-e053-3a05fe0a2c94
|
51
|
|
SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries, file e309ade4-72bb-3969-e053-3a05fe0a2c94
|
51
|
|
Triple therapy in COPD: New evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide, file e309ade4-ab2a-3969-e053-3a05fe0a2c94
|
51
|
|
Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma, file e309ade4-c022-3969-e053-3a05fe0a2c94
|
51
|
|
Primary pulmonary epithelioid hemangioendothelioma: A rare cause of PET-negative pulmonary nodules, file e309ade4-c4b7-3969-e053-3a05fe0a2c94
|
51
|
|
Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations, file e309ade2-b996-3969-e053-3a05fe0a2c94
|
50
|
|
Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting, file e309ade4-1ae1-3969-e053-3a05fe0a2c94
|
50
|
|
Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: Meta-analysis of MENSA and MUSCA, file e309ade4-9fa8-3969-e053-3a05fe0a2c94
|
50
|
|
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA, file e309ade4-a3f6-3969-e053-3a05fe0a2c94
|
50
|
|
Asthma COPD Overlap PRO-CON Debate. ACO: The Mistaken Term, file e309ade4-ab4c-3969-e053-3a05fe0a2c94
|
50
|
|
Interleukin-13 and-4 expression in the central airways of smokers with chronic bronchitis, file e309ade0-2ded-3969-e053-3a05fe0a2c94
|
49
|
|
A multinational observational study identifying primary care patients at risk of overestimation of asthma control, file e309ade4-701a-3969-e053-3a05fe0a2c94
|
49
|
|
Inhaled corticosteroid containing combinations and mortality in COPD, file e309ade4-b0ad-3969-e053-3a05fe0a2c94
|
49
|
|
Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO), file e309ade4-b409-3969-e053-3a05fe0a2c94
|
49
|
|
Blood eosinophil count and exacerbation risk in patients with COPD, file e309ade4-b54a-3969-e053-3a05fe0a2c94
|
49
|
|
COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma, file e309ade0-2dec-3969-e053-3a05fe0a2c94
|
48
|
|
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial, file e309ade4-8490-3969-e053-3a05fe0a2c94
|
48
|
|
Diffuse pulmonary meningothelial like nodules simulating metastatic thymoma, file e309ade4-d2a9-3969-e053-3a05fe0a2c94
|
48
|
|
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: A randomized noninferiority trial, file e309ade4-1651-3969-e053-3a05fe0a2c94
|
47
|
|
Comparative effectiveness of triple therapy versus dual bronchodilation in COPD, file e309ade2-c7cc-3969-e053-3a05fe0a2c94
|
46
|
|
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD, file e309ade4-7ea1-3969-e053-3a05fe0a2c94
|
46
|
|
Asthma progression and mortality: The role of inhaled corticosteroids, file e309ade4-a2ba-3969-e053-3a05fe0a2c94
|
46
|
|
The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision, file e309ade4-bb90-3969-e053-3a05fe0a2c94
|
46
|
|
Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study, file e309ade4-c737-3969-e053-3a05fe0a2c94
|
46
|
|
Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure, file e309ade4-d385-3969-e053-3a05fe0a2c94
|
46
|
|
TGF-β Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD, file e309ade3-480e-3969-e053-3a05fe0a2c94
|
45
|
|
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians, file e309ade4-7fe8-3969-e053-3a05fe0a2c94
|
45
|
|
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD, file e309ade4-afe4-3969-e053-3a05fe0a2c94
|
45
|
|
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline, file e309ade3-b15f-3969-e053-3a05fe0a2c94
|
44
|
|
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis, file e309ade4-3cc2-3969-e053-3a05fe0a2c94
|
44
|
|
Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD, file e309ade4-a4f5-3969-e053-3a05fe0a2c94
|
44
|
|
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD, file e309ade0-8555-3969-e053-3a05fe0a2c94
|
43
|
|
Extrafine beclometasone diproprionate/formoterol fumarate: A review of its effects in chronic obstructive pulmonary disease, file e309ade4-4f05-3969-e053-3a05fe0a2c94
|
43
|
|
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease, file e309ade4-913f-3969-e053-3a05fe0a2c94
|
43
|
|
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma, file e309ade4-c730-3969-e053-3a05fe0a2c94
|
43
|
|
From Gold 0 to Pre-COPD, file e309ade4-102a-3969-e053-3a05fe0a2c94
|
42
|
|
Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease, file e309ade4-f6de-3969-e053-3a05fe0a2c94
|
42
|
|
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation, file e309ade0-ce14-3969-e053-3a05fe0a2c94
|
41
|
|
Treatment strategies for asthma: Reshaping the concept of asthma management, file e309ade4-6b97-3969-e053-3a05fe0a2c94
|
41
|
|
Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol, file e309ade4-c46e-3969-e053-3a05fe0a2c94
|
41
|
|
Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative, file e309ade4-c9c3-3969-e053-3a05fe0a2c94
|
41
|
|
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function, file e309ade4-d4a8-3969-e053-3a05fe0a2c94
|
40
|
|
New drugs targeting Th2 lymphocytes in asthma, file e309ade5-0962-3969-e053-3a05fe0a2c94
|
40
|
|
Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy, file e309ade5-0ab3-3969-e053-3a05fe0a2c94
|
40
|
|
Ectopic thymoma simulating a pericardial cyst: case report, file e309ade0-2bea-3969-e053-3a05fe0a2c94
|
39
|
|
Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study, file e309ade4-6f51-3969-e053-3a05fe0a2c94
|
39
|
|
FN3K expression in COPD: a potential comorbidity factor for cardiovascular disease, file e309ade4-8e73-3969-e053-3a05fe0a2c94
|
39
|
|
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions, file e309ade4-b185-3969-e053-3a05fe0a2c94
|
39
|
|
Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER, file e309ade4-bb92-3969-e053-3a05fe0a2c94
|
39
|
|
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD, file e309ade4-a6ab-3969-e053-3a05fe0a2c94
|
38
|
|
ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy, file e309ade4-af6d-3969-e053-3a05fe0a2c94
|
38
|
|
Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma, file e309ade5-097b-3969-e053-3a05fe0a2c94
|
38
|
|
The burden of self-reported rhinitis and associated risk for exacerbations with moderate-severe asthma in primary care patients, file e309ade4-a3aa-3969-e053-3a05fe0a2c94
|
37
|
|
Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies, file e309ade4-dd19-3969-e053-3a05fe0a2c94
|
37
|
|
Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients, file e309ade4-f573-3969-e053-3a05fe0a2c94
|
36
|
|
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study, file e309ade5-209c-3969-e053-3a05fe0a2c94
|
36
|
|
Inhaled triple therapy in chronic obstructive pulmonary disease – Authors' reply, file e309ade5-1d96-3969-e053-3a05fe0a2c94
|
34
|
|
Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study, file e309ade4-8935-3969-e053-3a05fe0a2c94
|
32
|
|
Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE), file 46a8c934-c458-4122-90a9-0ac123b4779c
|
24
|
|
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal, file d8d8ff24-e8dd-4f11-a365-7b33ac20f98e
|
24
|
|
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease, file 31219c79-38ba-4144-95df-3d2ae06d23ae
|
22
|
|
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management, file e309ade3-e7e5-3969-e053-3a05fe0a2c94
|
21
|
| Totale |
11.028 |